Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma Inc operates as a clinical-stage biopharmaceutical company developing small molecule therapeutics for neurodegenerative diseases, with news coverage reflecting the company's progression through clinical trial milestones and regulatory developments. The company's news flow centers on clinical trial results, regulatory filings, corporate development activities, and financial disclosures typical of publicly traded biotechnology firms.
News coverage for Athira Pharma typically encompasses several key categories. Clinical trial announcements reveal data from ongoing studies evaluating the company's drug candidates in various patient populations. These updates include trial enrollment milestones, interim data releases, and topline results from completed studies. Regulatory filings and patent developments also generate news as the company navigates the pharmaceutical approval process and protects its intellectual property portfolio.
Corporate developments such as licensing agreements, research collaborations, and strategic partnerships appear in Athira's news stream as the company forms relationships with academic institutions, contract research organizations, and potential commercial partners. Financial disclosures including quarterly earnings reports, capital raises, and analyst presentations provide transparency into the company's operational progress and financial position.
Athira's news also reflects the broader biotechnology sector dynamics, including updates on competitive developments in neurodegenerative disease research, changes in regulatory guidance for clinical trials, and industry conference presentations where the company shares scientific data. Understanding these news patterns helps investors track the company's development pipeline progression and strategic positioning within the neuroscience therapeutics landscape.
Following Athira Pharma's news feed provides insight into the complex pathway of drug development, from preclinical research through clinical trials and toward potential regulatory approval. The news archive documents the company's evolution and offers context for evaluating progress against industry benchmarks for clinical-stage pharmaceutical development.
Athira Pharma (NASDAQ: ATHA) announced its participation in the Alzheimer’s Association International Conference (AAIC) 2022, taking place from July 31 to August 4, 2022. Chief Medical Officer Hans Moebius will present results from the ACT-AD Phase 2 proof-of-concept study on fosgonimeton (ATH-1017) targeting mild-to-moderate Alzheimer’s patients. The conference will include discussions on novel Alzheimer’s treatments, with Athira presenting data on its small molecule HGF/MET platform aimed at neuroprotection and cognitive improvement.
Athira Pharma (ATHA) announced topline results from its ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The primary endpoint of statistically significant change in ERP P300 latency was not met, suggesting diminished effect when combined with standard-of-care AChEIs. However, a subgroup analysis indicated improved ERP P300 latency and cognitive performance in patients on fosgonimeton monotherapy compared to placebo. Fosgonimeton demonstrated a favorable safety profile, and insights gained will inform the ongoing LIFT-AD study.
Athira Pharma, Inc. (NASDAQ: ATHA) has established a Scientific Advisory Board (SAB) comprising leading experts in neurology and neurodegenerative diseases. The board, chaired by Athira's Chief Medical Officer, Dr. Hans Moebius, aims to provide strategic guidance for the development of Athira's novel small molecule compounds targeting conditions like Alzheimer’s and Parkinson’s disease. SAB members include prominent researchers from esteemed institutions, enhancing Athira’s capability in advancing its pipeline for neurological treatments.
Athira Pharma (NASDAQ: ATHA) announced that its shareholders have approved the election of three new independent directors: Joseph Edelman, John M. Fluke, Jr., and Grant Pickering. CEO Mark Litton expressed gratitude for shareholder support, emphasizing the directors' contributions during a crucial phase for the company. Athira will continue to advance its clinical trials, focusing on its lead drug candidate, fosgonimeton (ATH-1017), aiming to enhance shareholder value. The final voting results will be disclosed in a Form 8-K filing with the SEC.
Athira Pharma (NASDAQ: ATHA) has announced that its board recommends shareholders vote 'FOR' its three qualified director nominees on the WHITE proxy card. As Richard A. Kayne suspends his proxy contest, the board expresses gratitude for shareholder support and emphasizes its commitment to advancing Athira's strategy, especially with topline results from the Phase 2 ACT-AD study expected soon. The board believes it is well-equipped to drive company success, focusing on its developments in neurodegenerative diseases like Alzheimer’s and Parkinson’s.
On May 16, 2022, Ric Kayne, a shareholder of Athira Pharma (NASDAQ: ATHA), announced the suspension of his campaign for board election amid concerns about the company's future leadership and strategy for ATH-1017. Despite expressing optimism about the drug's potential, Kayne acknowledged that a close vote could lead to a contentious board dynamic. He emphasized shareholder engagement, urging them to voice their opinions, while asserting the need for enhanced clinical management in light of upcoming trial results.
Athira Pharma (NASDAQ: ATHA) announced promising preclinical findings for its small molecules, ATH-1018 and ATH-1019, targeting the HGF/MET signaling pathway. Presented at the 2022 Peripheral Nerve Society Annual Meeting, results showed significant improvement in pain-related behaviors in a diabetic neuropathy model. Notably, the effects persisted even after the compounds were cleared from plasma, suggesting long-lasting benefits. Athira aims to further evaluate these candidates to enhance its pipeline for treating diabetic neuropathy and other neurodegenerative conditions.
Athira Pharma (NASDAQ: ATHA) reported its Q1 2022 financial results and discussed progress in clinical studies, including the ACT-AD Phase 2 Alzheimer's study set to release topline data by the end of Q2 2022. The company increased R&D expenses to $14.5 million, up from $7.4 million in Q1 2021, and general and administrative costs surged to $8.9 million due to headcount growth. The net loss also widened to $21.0 million, or $0.56 per share, compared to $8.9 million, or $0.25 per share, in the same period last year.
Ric Kayne, a shareholder of Athira Pharma (NASDAQ: ATHA), has called for immediate changes to the board of directors, citing poor decision-making that has led to significant shareholder value destruction. In a letter to shareholders, Kayne outlines various missteps, including governance failures and management issues, urging shareholders to support his candidacy and that of George Bickerstaff at the upcoming annual meeting on May 19, 2022. He emphasizes the need for experienced leadership to restore confidence and improve the company's clinical trial oversight.
Athira Pharma (NASDAQ: ATHA) urges shareholders to vote ‘FOR’ its independent director nominees at the Annual Meeting on May 19, 2022. The company emphasizes the importance of using the WHITE proxy card over any blue cards from Richard Kayne. Leading proxy advisors, ISS and Glass Lewis, recommend supporting Athira's nominees, highlighting the board’s effectiveness and strategic focus on advancing fosgonimeton (ATH-1017) for neurological diseases. Results from the Phase 2 ACT-AD study are anticipated by the end of Q2 2022, amidst ongoing efforts to enhance shareholder value.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
